Fc fusion as a platform technology: potential for modulating immunogenicityDitza Levin, Zuben E. Sauna, Basil Golding et al.|Trends in biotechnology|2014Cited by 204
Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse modelDitza Levin, Basil Golding, Erin Burch et al.|Journal of Thrombosis and Haemostasis|2017Cited by 7
Fusion of Fc domain to Factor IX (FIX) modulates the Th2 biased response to FIX and triggers Th1 immunity in hemophilia B treated mice.Ditza Levin, Basil Golding, H. A. Daniel Lagassé et al.|The Journal of Immunology|2017Cited by 0